Dipendra Kumar Mandal

Dipendra Kumar Mandal

Auto-generated profile, based on publicly available information

Dipendra Kumar Mandal

Central Department of Biotechnology, Tribhuvan University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2020 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
DMDipendra Kumar Mandal
Dipendra Kumar Mandal
SSShiv Kumar Sah
Shiv Kumar Sah
SMShyam Kumar Mishra
Shyam Kumar Mishra
SSSangita Sharma
Sangita Sharma
HKHari Prasad Kattel
Hari Prasad Kattel
BPBharat Pokharel
Bharat Pokharel
Background. Extended-spectrum β-lactamase (ESBL)- and AmpC-β-lactamase-producing Enterobacteriaceae have recently emerged as a public threat in the treatment of nosocomial as well as community-acquired infections. Very little information is currently available about its existence in Nepal. We, therefore, aim to determine the prevalence of ESBL and AmpC-β-lactamase-producing Enterobacteriaceae and also to determine their drug resistance pattern. Methods. During a 6-month period (November 2014–April 2015), a total of 190 stool specimens from 190 participants were obtained from different population. Of the total 260 fecal isolates, 152 from outpatient department (OPD) and 108 from healthy volunteer were collected. Stool specimens were cultured and enterobacterial isolates were subjected to antimicrobial susceptibility tests according to the standard microbiologic guidelines. ESBL was screened using ceftazidime (CAZ, 30 μg) and cefotaxime (CTX, 30 μg) disks and confirmed by double-disk synergy test. AmpC-β-lactamase enzyme production was detected by the aminophenylboronic acid inhibitor-based detection method. Antibiotic susceptibility test was performed for ESBL-positive isolates as per the Kirby-Bauer disk diffusion method, and interpretation was done according to CLSI (Clinical and Laboratory Standard Institute). Results. The prevalence of ESBL, AmpC-β-lactamases, and coproducer (ESBL + AmpC-β-lactamase) producing Enterobacteriaceae in OPD participants were 30.92%, 18.4%, and 13.81%, respectively, while 25%, 6.4%, and 1.8% in healthy population. ESBL-producing E. coli was 70.2% followed by K. pneumoniae (12.7%), and among AmpC-β-lactamase producer, E. coli were detected in half of the isolates (14/28, 50.0%) among OPD patients. Similarly, E. coli remained the most frequent ESBL producers 21/27 (77.8%) followed by K. pneumoniae 4/27 (14.21%) in healthy participants, and K. pneumoniae 5/7 (71.42%) and C. freundii 2/7 (28.57%) were detected highest among AmpC-β-lactamase-producing isolates. All isolates were highly sensitive (100%) to imipenem in both OPD and healthy participants. Conclusion. Our study revealed a high prevalence of ESBL- and AmpC-β-lactamase-producing enteric pathogen in Nepalese OPD and healthy population. The significant increase of these isolates and increased rate of drug resistance indicates a serious threat that stress the need to implement the surveillance system and a proper control measure so as to limit the spread of ESBL-producing Enterobacteriaceae (ESBL-PE) in both OPD as well as in community. Therefore, healthcare providers need to be aware that ESBL- and AmpC-β-lactamase-producing strains are not only circulating in hospital environments but also in the community and should be dealt with accordingly.

7 July 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
DMDipendra Kumar Mandal
Dipendra Kumar Mandal
EUElisha Upadhyaya
Elisha Upadhyaya
PDPuja Dahal
Puja Dahal
GAGaurav Adhikari
Gaurav Adhikari
RPRojina Pandey
Rojina Pandey
RMRajani Malla
Rajani Malla
Klebsiella pneumoniae is an opportunistic pathogen with rising multidrug resistance and biofilm-related infections. Molecular and phage characterization is crucial to understand resistance mechanisms and explore alternative therapies, such as phage therapy. Whole-genome sequencing and antibiotic susceptibility testing were performed on hospital-isolated K. pneumoniae (KP6697), followed by multilocus sequence typing (MLST), plasmid replicon analysis, and antimicrobial resistance gene (AMR) profiling using bioinformatics tools. Phages were isolated and characterized by electron microscopy, with assessments of anti-biofilm activity, lytic efficacy, stability, and host range. Phage genomes were sequenced to identify functional genes. The host K. pneumoniae (KP6697) was multidrug-resistant, exhibiting resistance to 18 of 22 tested antibiotics. Genome analysis identified it as sequence type 16 (ST16) with 8 plasmid replicons and 23 AMR genes, including bla CTX-M-15 , bla NDM-5 , and bla OXA-181 . Functional annotations revealed extensive metabolic versatility and a rich repertoire of genes for biofilm formation, quorum sensing, secretion systems, and stress response. A lytic phage, Phage_KP6697_Omshanti, was isolated and classified as a Caudoviricetes member with a 45.3-kb genome encoding lysis, replication, and structural genes. The phage demonstrated short latency, high burst size, acceptable thermal and pH stability, and moderate host range against multiple CRKP and other bacterial isolates. Importantly, microscopy confirmed its ability to inhibit and degrade biofilms at multiple stages, highlighting its strong therapeutic potential. Lytic Phage_KP6697_Omshanti, with depolymerase and endolysin activity, isolated from carbapenem-resistant KP6697, showed high burst size, biofilm disruption, and had essential genomic traits suggesting its potential use as an anti-CRKP agent. IMPORTANCE: Klebsiella pneumoniae is increasing multidrug resistance and robust biofilm formation pose severe clinical challenges, limiting treatment options. Understanding the molecular basis of its resistance and exploiting bacteriophages with strong biofilm-disrupting properties provide promising alternative therapeutic strategies. This study highlights the isolation and genomic characterization of a lytic phage with potent anti-biofilm activity against carbapenem-resistant K. pneumoniae , underscoring its potential in combating resistant infections.